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Abstract
Background:  The use of low-dose aspirin has been reported to be associated with an  increased
risk of upper gastrointestinal complications (UGIC). The coating of  aspirin has been proposed as
an approach to reduce such a risk. To test this  hypothesis, we carried out a population based case-
control study.
Methods:  We identified incident cases of UGIC (bleeding or perforation) aged 40 to 79  years
between April 1993 to October 1998 registered in the General Practice  Research Database.
Controls were selected randomly from the source population.  Adjusted estimates of relative risk
(RR) associated with current use of aspirin  as compared to non use were computed using
unconditional logistic  regression.
Results:  We identified 2,105 cases of UGIC and selected 11,500 controls. Among them,  287
(13.6%) cases and 837 (7.3%) controls were exposed to aspirin, resulting in  an adjusted RR of 2.0
(1.7-2.3). No clear dose-effect was found within the  range of 75-300 mg. The RR associated with
enteric-coated formulations (2.3,  1.6-3.2) was similar to the one of plain aspirin (1.9, 1.6-2.3), and
no  difference was observed depending on the site. The first two months of  treatment was the
period of greater risk (RR= 4.5, 2.9-7.1). The concomitant  use of aspirin with high-dose NSAIDs
greatly increased the risk of UGIC (13.3,  8.5-20.9) while no interaction was apparent with low-
medium doses (2.2,  1.0-4.6).
Conclusions:  Low-dose aspirin increases by twofold the risk of UGIC in the general  population
and its coating does not modify the effect. Concomitant use of  low-dose aspirin and NSAIDs at
high doses put patients at a specially high risk  of UGIC.
Background
Upper gastrointestinal complications (UGIC) are the
major risk associated  with aspirin use [1,2,3,4]. As with
non-aspirin non-steroidal  antiinflammatory drugs
(NSAIDs), dose appears to be a major determinant, but
even with low (300/325 mg) or very low doses (75 mg) a
residual amount of risk  seems to persist [3,4].
It has been postulated that enteric-coated formulations
of aspirin, designed  to resist the disintegration in acid
environment and pass by the stomach  without dissolu-
tion, may have an impact in reducing the risk [ 5]. The
idea behind this strategy is grounded on the belief that
gastric  damage caused by aspirin is mainly due to a local
effect [ 6]. Results from several endoscopic studies car-
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ried out in healthy  volunteers supported this hypothesis
showing that enteric-coated aspirin caused  less gastric
erosion and microbleeding than regular formulations
[7,8,9]. However, it  is known that these lesions are not
good predictors of major upper  gastrointestinal compli-
cations. From an epidemiological point of view the  ques-
tion is a matter of controversy as well. Two case-control
studies have  reported data on the effect of enteric-coated
preparations on upper  gastrointestinal bleeding, yield-
ing to apparently opposite results. Weil et al  [3] conclud-
ed that "enteric-coated aspirin ... may be  free of risk"
after estimating an odds ratio of 1.6 but with a wide 95%
confidence interval (0.5-4.9). On the other hand, Kelly et
al [ 4] found a risk of 2.6 (95% confidence interval, 1.4-
5.3) which was  essentially similar to the one estimated
for plain aspirin when the effect of  dose was taken into
account.
In order to shed some light onto this issue and to esti-
mate the specific  aspirin-related risk of upper gastroin-
testinal bleeding and perforation, its  relation with dose
and duration of treatment, as well as the potential  inter-
action between aspirin and other drugs (particularly
NSAIDs), we used data  from a case-control study de-
signed to estimate risks of UGIC associated with  drugs
and other factors [10].
Subjects and methods
A case-control study was carried out using data from the
UK-based General  Practice Research Database. This da-
tabase has been described extensively  elsewhere [11].
Briefly, it contains details of  patients' demographics,
medical diagnosis, referrals to consultants and  hospi-
tals, and prescriptions. The accuracy and completeness
of these data have  been validated in previous studies
[12].
Case definition and ascertainment
The source population was encompassed by patients
aged 40 to 79 years  between April 1993 and October
1998, with at least 2 years' enrollment with  their general
practitioner. Patients with cancer, oesophageal varices,
Mallory-Weiss disease, alcoholism, liver disease, or co-
agulopathies were  excluded. We identified incident cas-
es of upper gastrointestinal bleeding or  perforation, and
reviewed their computerised profiles. The date of first
diagnosis was used as the index date. Patients with any of
the exclusion  criteria mentioned above in the 2 months
after index date, those discharged  from hospital in the
two previous weeks, and subjects with the source of the
bleed/perforation in the oesophagus or lower gastroin-
testinal tract were not  retained as cases. A patient was
considered a case of UGIC when no exclusion  criterion
was found, and the specific site of bleed/perforation was
located in  the stomach or duodenum or the clinical diag-
nosis was peptic ulcer. Only  patients referred to a spe-
cialist or admitted to hospital were retained as  cases. To
confirm the validity of our computer-based case ascer-
tainment, we  requested from the general practitioners a
copy of the paper-based records of  100 randomly sam-
pled patients. We received records for 99 patients of
which 98  were confirmed as cases. We therefore decided
to study all patients classified  as cases on the basis of the
review of computerised information [13]. Patients with a
fatal outcome within a month of the  beginning of the ep-
isode were considered as fatal cases.
Control selection
All patients from the source population were assigned a
random date during  the study period. If such random
date fell within his/her observation period,  that patient
was considered eligible as control. From this population
we  randomly selected 11,500 patients frequency-
matched with cases for age  (interval of 1 year), sex and
calendar year. We applied to controls the same  exclusion
criteria used for cases [14].
Exposure definition
We defined patients as "current users" when the supply
of a prescription for  aspirin lasted until the index date or
ended within the period of 30 days  before index date,
"recent users" when the supply ended between 31 to 180
days  before the index date, "past users" if the supply
ended more than 180 days  before and "non-users" if no
prescription was ever recorded before the index  date.
Among current and recent use categories we also ex-
plored narrower  exposure windows. Among current us-
ers, we studied the effect of dose, treatment  duration
and formulation of aspirin. For the estimation of daily
dose two  different approaches were followed: 1) the dose
instructed by the general  practitioner and 2) the average
dose calculated by dividing the number of  tablets sup-
plied (provided that at least three prescriptions were
written  before index date) over the treatment period. Al-
though a wide range of  different strengths of low-dose
aspirin are available in the U.K., the most  widely used by
general practitioners are 75 mg and 300 mg. A number of
physicians prescribed a 300 mg tablet to be taken in al-
ternate days; from a  risk perspective, we considered
such patients closer to the 300 mg group and  were in-
cluded in this category. Duration of treatment was calcu-
lated by adding  up the time corresponding to
consecutive prescriptions of aspirin before the  index
date, considering two prescriptions as consecutive when
the interval  between the end of supply of one prescrip-
tion and the start of the next one was  less than 120 days
(this interval was meant to make a clear separation be-
tween  those patients actually starting a new treatment
course with aspirin from those  having a poor compli-
ance). Further, among current users we distinguishedBMC Clinical Pharmacology (2001) 1:1 http://www.biomedcentral.com/1472-6904/1/1
between those patients whose aspirin treatment course
was the first ever  recorded in the GPRD over the study
period, and those with a previous (or  distant) use. The
indication of aspirin was studied among current users in
two  random samples of 100 subjects each among cases
and controls. All manual review  was done blinded to the
status of each patient (case or control).
We also evaluated the exposure to other drugs such as
non-aspirin NSAIDs,  paracetamol, steroids, anticoagu-
lants, selective serotonin reuptake inhibitors  and antiul-
cer drugs (antacids, H2-blockers and omeprazol).
Among current users  of NSAIDs, we distinguished be-
tween low-medium and high daily doses using the  cut-
off limits described in previous studies [10].
Analysis
We used unconditional logistic regression to compute
adjusted estimates of  relative risk and 95% confidence
intervals (95% CI) for current use of aspirin  as compared
to non-use. Two different outcomes were studied: upper
gastrointestinal bleeding (UGIB) and perforation. The
location of the lesion  was considered in the analysis
when number of cases allowed for that. Also, we  exam-
ined separately fatal cases. The following covariates were
studied as  potential confounders: history of upper gas-
trointestinal disorder (dyspepsia,  peptic ulcer, upper
gastrointestinal bleeding/perforation), smoking status
(information available for 84% of study population), al-
cohol consumption  (information available for 58% of
study population), and current use of drugs  related with
an increased risk of upper gastrointestinal complica-
tions:  non-aspirin NSAIDs [15], anticoagulants, corti-
costeroids  [15], high-dose (> 2 grams) paracetamol [10]
and selective serotonin reuptake inhibitors [16]. The
matching factors were included in the model as well.  We
studied the interaction between aspirin and other drugs
by forming one  single term in the model for the joint ef-
fect. The relative excess risk due to  interaction (RERI)
was used as a measure of interaction and was calculated
as:  Relative risk (current joint use of "a" and "b")-rela-
tive risk (current use of  "a" only)- relative risk (current
use of "b" only) + 1, being "a" and "b" the  factors whose
interaction is being studied [17,18].
Results
We identified 1,833 cases of upper gastrointestinal
bleeding and 272 cases  of perforation. Cases and con-
trols did not differ by age group and sex (table  1). Among
bleeding cases, the lesion was located at the  stomach in
764 (42%) and the duodenum in 811 (44%), remaining
unspecified in  258 (14%); 4.1% of bleeding cases were fa-
tal. Among perforation cases, 36 (13%)  were located in
the stomach and 236 (87%) in the duodenum with a
case-fatality  rate of 21.0 %. Two hundred eighty seven
cases (13.6%) of upper  gastrointestinal bleeding (n=
248; 13.5%) or perforation (n= 39; 14.3%) were  current
users of aspirin, as compared to 837 current users among
controls  (7.3%) yielding to an adjusted RR of 2.0 (95%
CI: 1.7-2.3) for all cases (table  2). No material difference
was found when upper  gastrointestinal bleeding (2.0,
1.7-2.4) and perforation (1.7, 1.2-2.6) were  considered as
separate outcomes, or when location was taken into ac-
count  (gastric 2.0, 1.6-2.5; duodenal 1.7, 1.4-2.1). The
risk was essentially the  same either for fatal (1.8, 1.1-2.9)
or nonfatal (2.0, 1.7-2.4) cases. No  modification of the
relative risk estimates was observed by sex (males, 2.0
(1.6-2.4); females, 2.0 (1.5-2.6). The relative risks by age
group were as  follows: 40-59 years, 2.4 (1.3-4.4); 60-69
years, 2.3 (1.8-3.1); 70-79 years,  1.8 (1.4-2.2).
Table 1: Distribution of study population by sex and age group
Cases Controls
(N=2,105) (N=11,500)
Gender
Male 1,327 (63.0  %) 7,167 (62.3 %)
Age group
40-59 667 (31.7  %) 3,766 (32.8%)
60-69 627 (29.8  %) 3,392 (29.5%)
70-79 811 (38.5  %) 4,342 (37.8 %)
Table 2: Risk of UGIB and perforation associated with aspirin use
All cases Controls Adjusted RR*
(N=2,105) (N=11,500) (95%CI)
Non-use 1,696 10,157 1 (reference)
Current use (1-30) 287 837 2.0 (1.7-2.3)
Use within 1-7 259 771 2.0 (1.7-2.3)
days time window
Use within 8-30 28 66 2.3 (1.4-3.7)
days time window
Recent use (31-180) 37 123 1.5 (1.0-2.3)
Use within 31-60 14 45 1.7 (0.9-3.3)
days time window
Use within 61-180 23 78 1.5 (0.9-2.5)
days time window
Past use (>180) 85 383 1.1 (0.8-1.4)
* Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  NSAIDs, 
anticoagulants, steroids, SSRIs and paracetamol.BMC Clinical Pharmacology (2001) 1:1 http://www.biomedcentral.com/1472-6904/1/1
The indications for aspirin among a random sample of
100 cases were  secondary prevention of coronary heart
disease (47), secondary prevention of  cerebrovascular
ischaemic events (36), peripheral vascular disease (5),
other  cardiovascular disease (2), and analgesia (2). For
the remainder (8) the  indication was not unequivocally
identified from the patient profiles. The  distribution of
indications in a random sample of 100 controls was 50,
30, 5,  3, 2 and 10, respectively.
Seventy-five mg was the daily dose most frequently pre-
scribed (48%) in  controls, followed by 150 mg (27%),
300/325 mg (19%), and more than 325 mg  (6%). No
dose-effect relation was observed with aspirin within the
75-300 mg  range according to the instructions written
by the general practitioner (table  3). This remained true
when the analysis was restricted  to a specific lesion (ei-
ther bleeding or perforation) or to a specific location  (ei-
ther gastric or duodenal) (see additional material:
Appendix 1). Results did  not materially change when
only patients without any antecedents of  gastrointesti-
nal disorders (including dyspepsia) were considered (see
additional material: Appendix 2), or when we controlled
for use of antiulcer  drugs. For 149 patients (45 (16%)
cases and 104 (12%) controls) among current  users the
average daily dose estimated through the number of tab-
lets supplied  exceeded the cut-off values established to
separate different dose categories  (112, 225 and 400
mg). The replacement of the "instructed dose" by the av-
erage  dose did not make a significant change (table 3).
Nor did  the restriction of the analysis to patients with
consistent data for both  methods of aspirin dose assess-
ment.
Enteric-coated aspirin was associated with a risk of
UGIC (RR of 2.3,  1.6-3.2) similar to the one of plain as-
pirin (1.9, 1.6-2.3). Estimates hardly  changed when ana-
lysing separately bleeding and perforation, or gastric and
duodenal sites (table 4). As enteric-coated aspirin could
have been prescribed preferentially for those patients at
greater risk of  gastrointestinal damage, we performed a
sub-analysis including only individuals  without any an-
tecedent of upper gastrointestinal disorder: the relative
risk  estimate for enteric-coated aspirin was 2.7 (1.7-4.2)
and the one for plain  aspirin was 2.2 (1.8-2.8). The re-
sults did not change when additional  adjustment for an-
tiulcer drugs use was performed. Estimates of risk
associated  with aspirin formulation and stratified by
dose are shown in table 5. We observed a dose-response
starting at 300 mg with plain  aspirin but could not find
a similar pattern with enteric-coated.
As shown in table 6, the duration of treatment had an
impact upon the risk of upper gastrointestinal complica-
tion, being the first  two months of use the period of
greater risk (4.5, 2.9-7.1). Such a pattern was  observed
across different doses (table 7) or formulations  of aspirin
(see additional material: Appendix 3), though it was less
sharp  within the 75 mg dose and for enteric-coated prep-
arations. The indication for  aspirin in those patients
Table 3: Relation between aspirin dose and risk of UGIB and per-
foration  among current users as compared to non-use
All cases Controls Adjusted RR*
(N=2,105) (N=11,500) (95%CI)
Daily dose as instructed  
75 mg 141 420 1.9 (1.6-2.4)
150 mg 84 245 2.0 (1.5-2.6)
300 mg$ 54 163 2.0 (1.4-2.8)
600 + mg 8 9 4.0 (1.4-11.5)
Average daily dose +
<50 mg (irregular use) 4 29 0.7 (0.2-2.0)
51-111 135 383 2.1 (1.7-2.6)
112-225 91 258 1.9 (1.5-2.5)
226-400 48 151 2.0 (1.4-2.9)
> 400 9 16 3.1 (1.3-7.5)
* Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  NSAIDs, 
anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment  
for use of antiulcer drugs (antacids, H2-blockers and omeprazol) did 
not change  the estimates. $ Five cases and three controls taking 300 
mg in alternate days  were included in this category. Assigning those pa-
tients to the 150-mg category  hardly modified the results. + Calculated 
by dividing the number of tablets  supplied over the treatment period. 
For 161 patients (51 (18%) cases and 110  (13%) controls) less than 3 
prescriptions of aspirin were written, therefore  the instructed dose 
was still considered in these patients.
Table 4: Risk of UGIB and perforation associated with aspirin use 
according  to location, type of lesion and aspirin formulation
Adjusted*  RR (95% CI)
All cases UGIB Perforation
All sites Plain 1.9 (1.6-2.3) 2.0 (1.6-2.4) 1.6 (1.1-2.5)
Coated 2.3 (1.6-3.2) 2.2 (1.5-3.2) 2.4 (1.1-5.0)
Gastric Plain 2.0 (1.5-2.5) 2.0 (1.6-2.6) - $
Coated 2.2 (1.4-3.6) 2.3 (1.4-3.8)
Duodenal Plain 1.6 (1.3-2.1) 1.5 (1.2-2.0) 1.8 (1.1-2.8)
Coated 2.2 (1.4-3.4) 1.9 (1.1-3.2) 2.9#  (1.4-6.1)
* Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  NSAIDs, 
anticoagulants, steroids, SSRIs and paracetamol $ Only 3 cases of  gas-
tric perforation exposed to plain aspirin and none to coated aspirin # 
Based  on 9 exposed cases and 142 controlsBMC Clinical Pharmacology (2001) 1:1 http://www.biomedcentral.com/1472-6904/1/1
with shorter treatment duration (less than 2 months)
was related to cardiovascular disorders in 88% of cases
and 89 % of controls.  Among short-term users, those
who used aspirin for the first time appeared to  be at the
same relative risk as those with a previous non-consecu-
tive  prescription of aspirin ("distant use") (table 6). The
initial increased risk was clearly observed for bleeding le-
sions and less  markedly for perforation (see additional
material: Appendix 4).
The concomitant use of aspirin together with other non-
aspirin NSAIDs at  high dose increased substantially the
risk of major UGIC (relative risk 13.3,  8.5-20.9), far be-
yond the sum of their respective independent effects
(RERI=7.9, 2.0-13.8), while no interaction was apparent
when low-dose aspirin  was taken together with NSAIDs
at low-medium dose (RR of 2.2, 1.0-4.6) (table  8). The
interaction appeared to be greater for  perforation
(RR=30.3, 15.0-61.3; RERI=23.1, 2.2-44.2) than for
bleeding  (RR=10.8, 6.6-17.5; RERI= 5.7, 0.5-10.9).
Among bleeding lesions no difference  was found be-
tween the relative risk of the combination for those locat-
ed at the  stomach (RR=12.2, 6.8-21.9) and those located
at the duodenum (14.3, 8.3-24.5).  Both formulations of
aspirin presented this interaction with high-dose
NSAIDs  (plain, 12.7 (7.7-20.8); enteric-coated, 16.6
(5.9-46.3). No relevant  interaction beyond the sum of
the independent effects was observed between  aspirin
and high-dose paracetamol (4.5, 1.9-10.9) or aspirin and
steroids (1.9,  0.9-3.8). A small interaction was observed
between low-dose aspirin and  anticoagulants (5.5, 2.4-
12.7).
Discussion
The results of the present study show that the use of low-
dose aspirin for  prophylaxis of cardiovascular disorders
conveys a twofold increased risk of  upper gastrointesti-
nal bleeding and perforation in the general population.
This  increased risk is found over different categories of
age and sex. The effect of  aspirin applies equally to gas-
tric and duodenal sites.
We did not find a clear relation with aspirin daily dose
within the range  75-300 mg. Such a result did not
change when we restricted the analysis to  patients with-
out any antecedent of upper gastrointestinal disorder or
when we  adjusted for use of antiulcer drugs. This rea-
sonably excludes a potential  selection of patients with a
greater risk of UGIC to lower doses of aspirin.  Looking
for other sources of bias, we identified that in 13% of pa-
tients the  dose instructed by the general practitioner was
not consistent with the average  daily dose calculated by
counting the number of tablets supplied. We tried to  cor-
rect this by restricting the analysis to the population hav-
ing consistent  data with both methods and by replacing
the instructed dose by the average.  Neither of those cor-
rections yielded different results. Nevertheless, a  sug-
gestion of a greater risk associated with aspirin at higher
Table 5: Effect of aspirin formulation and dose on risk of UGIB 
and  perforation among current users as compared to non-use
All cases Controls Adjusted 
RR*
(N=2,105) (N=11,500) (95%CI)
Formulation/dose as instructed
Plain
≤  150 mg 201 626 1.9 (1.6-
2.2)
300 + mg 30 69 2.6 (1.6-
4.2)
Enteric-coated  
≤  150 mg 24 39 3.5 (2.0-
6.1)
300 + mg 32 103 1.8 (1.2-
2.8)
* Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  NSAIDs, an-
ticoagulants, steroids, SSRIs and paracetamol. Additional adjustment  
for antiulcer drugs use did not change the estimates.
Table 6: Effect of duration of treatment with aspirin on the risk of 
UGIB  and perforation among current users as compared to non-
use
All cases Controls Adjusted 
RR*
(N=2,105) (N=11,500) (95%CI)
Days of treatment
(consecutive prescriptions)
1-60 (all users) 40 52 4.5 (2.9-
7.1)
First-ever users 25 32 4.6 (2.7-
8.1)
Distant users 15 20 4.2 (2.0-
8.6)
61-180 34 71 2.7 (1.7-
4.2)
181-730 96 286 1.9 (1.5-
2.5)
>730 117 428 1.6 (1.3-
2.0)
*Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  NSAIDs, 
anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment  
for antiulcer drugs use did not change the estimates.BMC Clinical Pharmacology (2001) 1:1 http://www.biomedcentral.com/1472-6904/1/1
doses within the  range 75-300 mg versus lower doses
was found among users of the plain  formulation and
among short-term users (first 60 days of treatment). Fi-
nally,  although the confidence intervals for lower doses
are reasonably narrow, some  statistical uncertainty re-
mains and a dose-effect cannot be excluded;  therefore,
the use of the lowest dose shown effective is still the best
strategy to minimise risk.
The enteric-coated formulations appear not to protect
from the  aspirin-induced risk of upper gastrointestinal
bleeding, irrespective of the  dose, neither for gastric nor
for duodenal lesions. This observation adds up to  previ-
ous results from other investigators [4]. Assuming  that
the coating of aspirin effectively spares the stomach from
its topical  adverse effect, such results cast doubts on the
overall contribution of the  local effect in serious bleed-
ing lesions observed among aspirin users. Instead,  our
findings support the hypothesis that the effect of aspirin,
both plain and  enteric-coated, on upper gastrointestinal
bleeding is mainly systemic mediated  through inhibition
of platelet thromboxane A2 synthesis [19] and/or inhibi-
tion of protective prostaglandin synthesis in  the gas-
troduodenal mucosa [20]. A local effect, however,
cannot be ruled out as a relevant contributor for aspirin-
induced perforation,  as most cases were located in duo-
denum, and no difference or, perhaps, a  slightly greater
risk was found with the coated formulation. A preferen-
tial  prescription of enteric-coated aspirin to patients
with antecedents of  gastrointestinal disorders does not
explain our results, since enteric-coated  aspirin users
with no such antecedents present a risk similar to the one
associated with plain aspirin.
Patients in the first two months after starting treatment
with aspirin are  at the greatest risk of presenting a major
UGIC. Thereafter, the risk goes down  and reaches a pla-
teau at around six months. This phenomenon has been
observed  by other researchers for aspirin [3] but re-
mains  controversial for other NSAIDs [10, 15]. It has
been suggested that this high hazard rate at the begin-
ning  of treatment could be an artefact induced by the use
of aspirin for early  symptoms of peptic ulcer. This possi-
bility can be reasonably ruled out in our  study because
almost 90% of cases who experienced bleeding or perfo-
ration early  after starting treatment with aspirin were
using it for prevention of  cardiovascular disorders, a
pattern of use identical to the one found for new  users
among controls. Another explanation argued for the de-
creasing risk with  the continuation of treatment has
been the "early withdrawal of population  susceptible to
damage" [3]. In order to explore this  possibility we di-
vided short-term users of aspirin (< 2 months) into  "dis-
tant users" and "first-ever users", depending on the
recording or not of a  remote non-consecutive prescrip-
tion for aspirin. We did not find any apparent  difference
in risk between these two groups. So, patients who
stopped treatment  with aspirin for whatever reason and
then started again after a washout period  of at least four
months, presented a similar risk during the first two
months  of treatment as first-ever users. By exclusion,
the duration response could be  explained by the third
mechanism postulated so far: the existence of an  adap-
tation of the gastrointestinal mucosa to the toxic action
of aspirin.  According to our results, this adaptation
process would take at least 2 months  to result into clini-
cal benefits. In striking contrast, a constant risk pattern
has been found with non-aspirin NSAIDs [10,15]. The
reasons for such discrepancy are unknown and should
be further studied. In our view, the explanation should
be searched in the  pharmacological differences of aspi-
rin as compared to non-aspirin NSAIDs. It is  well known
that aspirin has a much greater topical adverse effect on
the  stomach lining than non-aspirin NSAIDs [21] and
perhaps  the adaptive process concerns mainly this
mechanism of action.
The concurrent use of low-dose aspirin with high-dose
NSAIDs increases the  risk of UGIC by a factor of 13. Sim-
ilar findings have been obtained by others  for UGIB [3].
Our results strongly suggest that the  combination may
Table 7: Effect of duration of treatment with aspirin on the risk of 
UGIB  and perforation among current users as compared to non-
use by aspirin dose
All cases Controls Adjusted RR*
(N=2,105) (N=11,500) (95%CI)
Daily dose as instruct-
ed/
 
Days of treatment/
75 mg
1-60 17 32 3.2 (1.7-6.1)
61-180 20 37 2.9 (1.6-5.2)
181-730 53 166 1.7 (1.2-2.5)
>731 51 185 1.7 (1.3-4.6)
150 mg
1-60 13 11 6.6 (2.7-15.9)
61-180 11 23 2.7 (1.2-6.0)
181-730 26 83 2.0 (1.2-3.2)
>730 34 128 1.5 (1.0-2.2)
300 + mg
1-60 10 9 6.0 (2.2-16.2)
61-180 3 11 1.9 (0.5-7.1)
181-730 17 37 2.6 (1.4-4.9)
>730 32 115 1.7 (1.1-2.6)
*Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  NSAIDs, 
anticoagulants, steroids, SSRIs and paracetamol.BMC Clinical Pharmacology (2001) 1:1 http://www.biomedcentral.com/1472-6904/1/1
have a particular impact on the risk of perforation (lower
confidence interval of 15). It is important to note that the
joint use of  low-dose aspirin with high-dose NSAIDs is
not unusual. In our random sample of  11,500 controls,
the prevalence of this combination was 3 per 1,000 sub-
jects, a  small figure in relative terms but large from a
public health perspective. On  the other hand, it is reas-
suring that no interaction beyond the sum of their  re-
spective effects was observed between aspirin and low-
medium NSAIDs, aspirin  and steroids, or aspirin and
paracetamol (even when this latter was taken at  doses
higher than 2 grams a day). Although we detected a slight
interaction of  low-dose aspirin and anticoagulants, the
confidence interval of the estimate is  wide and precludes
any firm conclusion.
The present study has some limitations. Aspirin pre-
scription is  systematically recorded in the GPRD, but its
over-the-counter use is only  recorded occasionally and
this could lead to a misclassification of aspirin  exposure.
Although misclassification of exposures collected pro-
spectively  before the occurrence of the event of interest
is usually close to  non-differential between cases and
controls, we evaluated the extent of the  under-recording
and the type of misclassification using external data from
a  recent study that analyzed the risk of peptic ulcer
bleeding associated with prophylactic aspirin and was
also performed in the UK [3]. The  authors interviewed
patients aged 60 and over and asked, among other
things,  information about all prescribed and self-admin-
istered drug intake. They found  that 27.1 % of cases and
15.9% of controls reported any use of aspirin in the
month before (16.5% and 8.3% respectively reported a
regular use). In our study  population, the prevalence of
aspirin use in the month before was 13.6% and  7.3%
(18.4% and 10.3% among the subjects aged 60 years or
older).  Interestingly, the case-control ratio of aspirin ex-
posure for the reference  study is 1.70, while the corre-
sponding ratio is 1.86 in our study (1.79 for the  older
group). These figures suggest that the under-recording of
OTC aspirin use  in our study is to a major extent non-dif-
ferential with respect to case status.  We performed a
sensitivity analysis assuming the worst case of a 50%
misclassification of aspirin users. The "true" crude OR
would be 2.3 instead of  the 2.1 observed. Therefore, it
seems unlikely that the underascertainment of  OTC as-
pirin use could have greatly distorted the estimate of as-
pirin effect in  our study. Other authors have recently
reached the same conclusion for OTC  NSAIDs [22]. It is
conceivable that the potential  misclassification of enter-
ic-coated preparations due to their higher price were  less
important than for the plain ones. This means that the
distortion to the  null would be weaker for the former
preparations, but assuming that the  misclassification
was non-differential with respect to case status, the im-
pact  of such difference would be negligible. We also ex-
amined the effects of a  differential misclassification with
respect to case status and only under the  unrealistic as-
sumption of a strong differential misclassification selec-
tively  affecting the higher doses within the range 75-300
mg of plain preparations,  could our results of lack of
dose-effect and lack of protective effect of  enteric-coated
preparations be explained.
We tried to control for other potential sources of bias, in-
cluding  channelling of patients with greater risk to low-
er-dose or enteric-coated  aspirin. However, as with all
observational studies, unmeasured or inaccurately
measured factors may lead to residual confounding.
Conclusions
Aspirin used at doses as low as 75 mg is still associated
with a moderate  risk of developing serious upper gas-
trointestinal complications. The coating of  the active
principle in order to spare the stomach does not reduce
the risk of  upper gastrointestinal complications, neither
for the stomach nor for the  duodenum. The first two
months of treatment seem to be the period of greater
risk, regardless the patient is first-ever user or not. Pa-
tients using  concomitantly low-dose aspirin and high-
dose nonaspirin NSAIDs are a subgroup  of patients with
Table 8: Effect of concomitant use of aspirin and NSAIDs among 
current users  as compared to non use of either drug (multiple us-
ers of NSAIDs were  excluded).
All cases 
(UGIB/Perfo-
ration)
Controls Adjusted RR* 
(N=2,105) (N=11,500) (95%CI)
Low-medium-dose 
NSAIDs only
83(71/12) 256 2.6 (2.0-3.4)
High-dose# NSAIDs 
only
254  (202/52) 413 4.3 (3.6-5.2)
Only aspirin 221 (201/20) 767 2.1 (1.8-2.5)
Aspirin + low-medium-
dose NSAIDs
9  (6/3) 34 2.2 (1.0-4.6)
Aspirin + high-dose# 
NSAIDs
57 (41/16) 36 13.3  (8.5-
20.9)
*Adjusted for sex, age, calendar year, antecedents of  gastrointestinal 
disorders, smoking status, alcohol consumption and use of  anticoagu-
lants, steroids, SSRIs and paracetamol. # High-dose NSAIDs:  Ace-
clofenac > 100, acemetacin > 120, diclofenac > 75, etodolac  > 400, 
fenbufen > 900, fenoprofen > 1200, flurbiprofen > 150,  ibuprofen > 
1200, indometacin > 75, ketoprofen > 100, mefenamic  acid > 1000, 
tiaprofenic acid > 450, azapropazone > 600, meloxicam  > 7.5, 
nabumetone > 1000, naproxen > 500, piroxicam > 10,  sulindac > 200, 
tenoxicam > 10 (all doses in mg).BMC Clinical Pharmacology (2001) 1:1 http://www.biomedcentral.com/1472-6904/1/1
a major increased risk of upper gastrointestinal  compli-
cations.
Abbreviations
UGIB: Upper gastrointestinal bleeding; UGIC: Upper
gastrointestinal  complications; NSAIDs: Non-steroidal
and anti-inflammatory drugs; RR; Relative  risk; GPRD:
General Practice Research Database.
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